|
|
||||||||
1 From the Cooperative Research Centre for Eye Research and Technology, Sydney/CSIRO Division of Molecular Science, Sydney/University of New South Wales, Sydney, NSW, Australia; and 2 University of North Texas Health Science Center, Department of Molecular Biology and Immunology, Fort Worth, Texas.
| Abstract |
|---|
|
|
|---|
-smooth muscle actin in order to affect
wound closure by contracting the surrounding matrix. Excessive
contraction results in the formation of unresolvable scars that are
undesirable in the corneal stroma. The authors tested the effect of
vitronectin and fibronectin on the contraction process associated with
corneal wound healing.
METHODS. Collagen gels were prepared and were exposed to different treatments
of fetal calf serum (FCS). The FCS used was either depleted of
fibronectin and vitronectin or contained a known concentration of
fibronectin, vitronectin, or both at 50 µg/ml. Contraction was
measured using image analysis and cross sections of contracted gels
were examined for
-smooth muscle actin expression using laser
confocal microscopy.
RESULTS. Fibroblasts seeded in collagen gels paralleled the morphologic characteristics and cell distribution of keratocytes in unwounded cornea. Matrix contraction was dependent on the presence of fibronectin and/or vitronectin where myofibroblasts were present. The cell-mediated contraction process was maximal at 0.5 x 105 fibroblasts/ml.
CONCLUSIONS. These studies showed that vitronectin or fibronectin is required for the myofibroblast-associated contraction to occur in this in vitro model of stromal wound healing. This model system shows a distinct potential for further studies relating to the corneal wound healing process.
| Introduction |
|---|
|
|
|---|
After an injury to the stroma, keratocytes adjacent to the wound are
activated to become CFs, which, in addition to other functions, are
believed to be responsible for the contraction process.3
4
These activated CFs assemble actin filaments similar to those in smooth
muscle cells5
and on this basis, have been named
myofibroblasts (MFs).3
4
The transformation of CFs into
MFs can be identified by the expression of
-smooth muscle actin
(
-SMA).6
Keratocytes in the unwounded normal
(quiescent) stroma do not express this protein.3
4
The role of MFs in contraction can be effectively studied using established in vitro models. Such models have been validated previously by Minami et al.,7 Zieske et al.8 and Dimitrijevich et al.9 10 The human model established by Dimitrijevich et al.9 10 is based on a fibroblast-seeded collagen type I gel (FSCG), which constitutes the stromal element. In all stromal models where fibroblasts are seeded into collagen gels, they are activated and become phenotypically modified to resemble the MFs that are present in the wounded stroma.11 Hence, the FSCG provides a three-dimensional, in vitro environment that closely resembles the wound healing state found in vivo, thus offering the opportunity to study the CF or MF response during this event.6 11 12 The FSCG model system is supported by studies that have demonstrated that CFs seeded into collagen gels have a similar distribution and appearance to those found in unwounded cornea.13 14 15 As a result, the FSCG system provides a good model for investigating CF/MF responses during wound healing.16 17 18 19 20 21 22
There are two schools of thought regarding the tissue contraction process during stromal wound healing. One of these proposes that the presence of a contractile force within cells is a response to the tension produced within the surrounding extracellular matrix.23 It is alternatively proposed that contraction is an action brought about by the resident cells (e.g., MFs) as they generate the motive force needed to reorganize the surrounding matrix.24 In support of the latter view, Welch et al.25 and Garana et al.1 proposed that the contraction is based on the interaction of intracellular stress fibers and extracellular fibronectin (Fn). They concluded that during wound healing, CFs undergo a phenotypic transformation to MFs, which contribute to contraction by pulling in and organizing the extracellular matrix. Studies of molecular linkages between the corneal MFs and the collagen fibers suggest that Fn may act as the connective bridge between resident fibroblasts and the adjacent fibrillar collagen matrix.26 Later work proposed that fibroblasts active in the wounding process attach to Fn and pull on the surrounding matrix.25 This suggestion was supported by Garana et al.1 who found that serum containing Fn enhanced the contraction process. Furthermore, this group identified the presence of extracellular Fn in the stroma at day 14 after a gape wound to the feline cornea. Because contraction of FSCGs was found to occur in medium containing serum that had been depleted of Fn,27 this brings to the fore the question of other components within the serum that may act in a similar way to Fn. Schafer et al.27 proposed that vitronectin (Vn) could replace Fn as a bridging molecule between fibroblasts and collagen. Vn is known to bind to collagen28 and shares with Fn the cell-binding domain of arginine-glycine-aspartate (RGD).29 30 To date, no evidence has emerged to support a role for Vn in wound contraction, and it remains to be shown definitively what role(s) Vn and Fn play in corneal wound healing.
This article presents evidence for the direct effect of Vn and/or Fn on fibroblast-induced contraction in a wound healing model of the corneal stroma. An FSCG model was used to determine the extent of contraction and the associated presence of MFs. The results identify an interchangeable requirement for Vn or Fn in the contractile process and provide further insight into the mechanism involved in the course of normal corneal wound healing.
| Materials and Methods |
|---|
|
|
|---|
FSCG Preparation
Collagen gels were quickly prepared at room temperature with one
part 10x Hams/F12 medium (ICN Biomedicals), one part reconstitution
buffer and eight parts collagen type I (Cellagen 0.3% pepsin
solubilized; ICN Biomedicals) as described in Dimitrijevich et
al.10
This mixture was inoculated with bovine CFs to a
final population density of 5.0 x 104
cells/ml (unless otherwise stated in the Results section), and 2 ml was
poured into individual semipermeable membrane inserts of 24-mm diameter
and 0.4-µm pore size (Corning Costar Corporation). These inserts were
placed in the wells of a six-well plate, and the gels were allowed to
polymerize for 60 minutes at 37°C. Culture medium was then added to
cover the top of the gel, and to the well, so that the nutrients were
supplied through the apical and basal surfaces. This assembly was
incubated at 37°C in a humidified atmosphere of 5%
CO2 in air. Acellular gels were used as controls
for all experiments.
Culture Media
Gels were maintained in keratinocyte serum-free medium (KSFM;
Gibco BRL Life Technologies, Grand Island, NY) and were supplemented
with either 2% (vol/vol) FCS or FCS stripped of Fn and Vn, termed
double-depleted serum (DD FCS). DD FCS was prepared according to
methods described by Engvall et al.31
to remove Fn and
Underwood et al.32
for Vn removal. Fn was removed from FCS
using a packed column of gelatin-Sepharose (Pharmacia, Sweden). The
Fn-depleted FCS was then fed through a monoclonal anti-bovine Vn
affinity column, to form DD FCS. Vn, which was added back to DD FCS to
form the treatment known as "Vn," was derived from the product
obtained from stripping intact FCS as described above. Commercially
available Fn (Sigma, St. Louis, MO) was used in the experiments in
which Fn was added back to DD FCS to form the treatment known as
"Fn." Protein concentrations for both Vn and Fn were determined
using bicinchoninic acid (BCA) protein assays (cat. no. 23223/4;
Pierce, Rockford, IL).
Measurement of Gel Contraction
To determine the degree of gel contraction, an Image Analysis
system (Q570; Cambridge Diagnostics, Billerica, MA) was used to measure
the surface area of the individual gels. The measured area was
subtracted from the original surface area of the collagen gel and
expressed as a percentage of initial size. Two experiments were
conducted in each case, with three replicate samples per treatment.
Hematoxylin and Eosin Staining
This technique was based on previously described
methods.33
34
FSCGs and intact bovine cornea were embedded
in Tissue-Tek OCT compound (Sakura Finetek, CA), snap-frozen, and
sectioned at 6-µm thickness onto gelatin-coated slides. Air-dried
sections were fixed by immediately immersing them in
formalin-acetic-alcohol (10%:85%:5% vol/vol, respectively) solution
for 30 seconds. Slides were stained with hematoxylin and eosin, mounted
in Gurr mounting medium (BDH Chemicals, Poole, UK), and viewed using a
Leica DMLB light microscope (Deerfield, IL).
Cell Visualization
A Cell Tracker Green fluorescent dye (Molecular Probes, Eugene,
OR) was used to visualize the CFs seeded in gels. The washed cell
pellet (see above) was resuspended in Cell Tracker Green solution that
was diluted in serum-free DMEM/F12 to a final concentration of 25 µM.
The final CF concentration was 1.0 x 104
cells/ml. This mixture was placed in a 37°C incubator for 50 minutes
and then inoculated into collagen gels as described above. The gels
were allowed to set and DMEM/F12 + 10% (vol/vol) FCS was added,
followed by incubation at 37°C for 48 hours in a humidified
atmosphere of 5% CO2 in air. Intact gels were
viewed by laser confocal microscopy (see below).
Immunohistochemistry
Collagen gels were embedded in Tissue-Tek OCT Compound at
days 9, 20, or 30, snap-frozen, and sectioned at 6-µm thickness onto
gelatin-coated slides. Sections were allowed to air dry and were then
blocked with 2% (wt/vol) bovine serum albumin in phosphate buffered
saline (PBS). The sections were then incubated at room temperature with
a monoclonal antibody to
-SMA (cat. no. A2547; Sigma) at a 1:20
dilution at room temperature for 60 minutes. Normal mouse serum was
used instead of
-SMA antibody as a negative control. Sections were
washed three times with PBS and stained with rabbit anti-mouse
fluorescein isothiocyanateconjugated antibody (DAKO Corporation,
Santa Barbara, CA) for 60 minutes at room temperature, during which
time they were kept in the dark. Sections were washed three times in
PBS and mounted in Fluorosave (Calbiochem, La Jolla, CA). Sections were
viewed by laser confocal microscopy (see below).
Laser Confocal Microscopy
Immunostained sections and Cell Trackerlabeled samples were
viewed with a scanning laser confocal microscope (TCS-40; Leica,
Heidelberg, Germany) using a 100x objective with a krypton/argon-mixed
gas laser and an excitation wavelength of 494 nm.
| Results |
|---|
|
|
|---|
|
|
|
|
|
-SMA). These
results are summarized in Table 1
. In the absence of Fn or Vn
(treatments using only DD FCS), no contraction was observed and no MFs
could be detected at day 9. The same treatment of FSCGs at day 20
indicated the presence of MFs (Fig. 5)
, despite minimal gel contraction (1.70%). MFs were also detected at
day 30 when both Fn and Vn were absent. The contraction of FSCGs with
this serum treatment also was increased at day 30 (9.7%).
|
Overall, these results showed that either Fn or Vn were involved in the contraction of FSCGs and that Vn was as effective as Fn in mediating this process.
| Discussion |
|---|
|
|
|---|
Our data showed that the presence of either Fn or Vn was essential for the MF-mediated contraction of FSCGs. It is well accepted that serum components play a critical role in fibroblast activation and postwounding contraction.6 12 37 38 However, the role of CF/MFs and their dependence on Fn or Vn in the wound-healing process remains to be determined.16 21 27 38 39 40 Fn is synthesized by CFs as an extracellular matrix component and is known to be present in increasing amounts in the postwounded corneal stroma.1 41 In the present study we have demonstrated that Fn increased the contraction of FSCGs, which was well above the level of contraction shown by the negative controls. We also showed that Vn had the same effect as Fn, supporting the hypothesis proposed by Schafer et al.27 that Vn can replace Fn in its role as a connective bridge between CFs and the surrounding collagen matrix. This sensitivity to Vn may relate to its localized presence in the corneal stroma.42 The experiments in which FSCGs were treated with both Vn and Fn showed that the contraction achieved was equal to that which occurred when Vn or Fn were used individually. This nonadditive effect was likely to be related to the fact that Vn and Fn competed for the same binding domain on collagen type I (see Gebb et al.28 ). Thus, when both Fn and Vn were present, Vn interacted preferentially with CFs and their surrounding collagen matrix. As expected, with intact FCS (positive control), the contraction was equal to that observed when Vn, Fn, or both were present. Integrins are likely to be involved with this connective bridge between CFs and their surrounding matrix proteins (Vn/Fn). Previous in vitro studies have in monolayer cultures demonstrated that CFs adhered to Fn and Vn via cell surface integrins.43 Fibronectin integrin receptors include alphav beta1/3/5, whereas vitronectin has been associated with alphav beta1/5 subunits.44
It was demonstrated in this study that in the absence of Vn and Fn (the
DD FCS treatment), MFs were unable to effectively cause FSCG
contraction at day 20. The low level of contraction that did occur at
day 20 may be attributed to trace amounts of endogenous Vn and/or Fn
synthesized by the resident CFs. This is presumably the case where FSCG
contraction increased at day 30. Under the same conditions, detection
of
-SMA demonstrated that CFs did transform to the MF phenotype. In
the light of results obtained from cell density studies, possible
reasons for this are discussed below.
We found that CF density in a three-dimensional matrix directly
affected the contractile capacity of the FSCG (Fig. 3)
in the presence
of serum or its components (Fn/Vn). This is consistent with reported
findings related to CF monolayer cell culture studies,37
which studied the effect of cell density on the expression of
-SMA
in vitro. By monitoring the expression of
-SMA it was found that
70% to 80% of the cell population had transformed to MFs in CF
cultures seeded at low density (103 cells/ml). In
CF cultures seeded at high density (105 cells/ml)
only 5% to 10% of the cell population was
-SMA
positive.37
The cell densitydependent MF transformation
mechanism is thought to be linked to a regulatory role by transforming
growth factor beta (TGF-ß).12
37
That is, CFs only
transformed to MFs when cellcell contact was limited by low cell
density and TGF-ß was present.37
Our studies confirm the
suggestion that at specific cell densities, and in the presence of
TGF-ß (likely to be present in DD FCS or FCS), CFs transformed to
MFs, which in the presence of Vn and/or Fn drew on their surrounding
matrix and initiated contraction. Hence, cell density and factors such
as TGF-ß are involved in the transformation of CFs into
MFs.12
37
However, the ability of the MFs to undergo
contraction of the surrounding matrix only occurred when Vn and/or Fn
were present. Conversely in the case when Vn and/or Fn were absent and
despite
-SMA being detected in FSCGs, these MFs were unable to bind
to collagen type I and contraction did not occur.
In conclusion, our studies have shown that MFs are dependent on Fn and/or Vn to initiate the contraction process. Considered together with the prior reports, the results of this study are consistent with the following interpretation: TGF-ß and a specific cell density are required for MF transformation, but it is only in the presence of Vn and/or Fn that these cells are able to connect to the surrounding type I collagen and initiate contraction. This work has also shown that the transformation of CFs to MFs is dependent on a specific cell density in a three-dimensional FSCG. This finding confirms the significance of the cell density in the process of MF transformation in FSCGs as previously reported for CF monolayer cultures.37 These results allow a direct comparison of the contracted and noncontracted FSCGs, and support the utility of noncontracted FSCGs, such as those used in this study. These FSCGs may prove valuable for future wound healing studies.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication January 7, 1999; revised April 28, 1999; accepted August 17, 1999.
Commercial relationships policy: C5.
Corresponding author: Lavinia Taliana, Department of Ophthalmology, Box 1183, Mount Sinai School of Medicine, One Gustave Levy Place, New York, NY 10029-6574. talial01{at}doc.mssm.edu
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. He and H. E. P. Bazan Epidermal Growth Factor Synergism with TGF-{beta}1 via PI-3 Kinase Activity in Corneal Keratocyte Differentiation Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2936 - 2945. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Carrier, A. Deschambeault, M. Talbot, C. J. Giasson, F. A. Auger, S. L. Guerin, and L. Germain Characterization of Wound Reepithelialization Using a New Human Tissue-Engineered Corneal Wound Healing Model Invest. Ophthalmol. Vis. Sci., April 1, 2008; 49(4): 1376 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Fogelgren, N. Polgar, K. M. Szauter, Z. Ujfaludi, R. Laczko, K. S. K. Fong, and K. Csiszar Cellular Fibronectin Binds to Lysyl Oxidase with High Affinity and Is Critical for Its Proteolytic Activation J. Biol. Chem., July 1, 2005; 280(26): 24690 - 24697. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, T. Sagara, K. Seki, S. Hirano, and T. Nishida Permissive Effect of Fibronectin on Collagen Gel Contraction Mediated by Bovine Trabecular Meshwork Cells Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4331 - 4336. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Taliana, M. D. M. Evans, S. D. Dimitrijevich, and J. G. Steele The Influence of Stromal Contraction in a Wound Model System on Corneal Epithelial Stratification Invest. Ophthalmol. Vis. Sci., January 1, 2001; 42(1): 81 - 89. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |